Recursion Pharmaceuticals, Inc. $RXRX Shares Sold by Liontrust Investment Partners LLP

Key Points

• Liontrust Investment Partners LLP reduced its stake in Recursion Pharmaceuticals by 36.1%, now holding 595,055 shares valued at approximately $3.15 million.
• Recursion Pharmaceuticals reported a loss of $0.41 EPS for the last quarter, which was below analysts' expectations, although revenue increased by 33.3% year-over-year.
• Wall Street analysts maintain an average rating of "Hold" on Recursion Pharmaceuticals with a consensus target price of $7.00, following mixed reviews from several research firms.

Liontrust Investment Partners LLP cut its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 36.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 595,055 shares of the company's stock after selling 336,672 shares during the quarter. Liontrust Investment Partners LLP owned approximately 0.15% of Recursion Pharmaceuticals worth $3,148,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc lifted its position in Recursion Pharmaceuticals by 0.3% in the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock valued at $2,774,000 after acquiring an additional 1,300 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Recursion Pharmaceuticals by 7.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock valued at $176,000 after acquiring an additional 1,875 shares during the period. Clear Creek Financial Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 9.8% during the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after acquiring an additional 1,907 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after acquiring an additional 2,026 shares during the period. Finally, QRG Capital Management Inc. increased its stake in Recursion Pharmaceuticals by 8.5% in the 1st quarter. QRG Capital Management Inc. now owns 28,515 shares of the company's stock valued at $151,000 after purchasing an additional 2,244 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded up $0.0150 on Thursday, reaching $4.7850. 7,042,297 shares of the company's stock were exchanged, compared to its average volume of 24,777,570. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -2.69 and a beta of 0.93. The business's 50-day moving average is $5.47 and its two-hundred day moving average is $5.80. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The company's revenue for the quarter was up 33.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.40) EPS. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Activity

In related news, insider Najat Khan sold 36,599 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.43% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of research analyst reports. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.